The ASAM National Practice Guideline Special Populations Webinar (July)
Recorded On: 07/26/2016
- Registration Closed
This special populations webinar series follows the National Practice Guideline overview webinar which outlined the recommendations from ASAM's National Practice Guideline for the Use of Medications in the Treatment of Opioid Use Disorders, which is the first guideline to include all medications to treat opioid use disorder.
Many of the medical risks associated with opioid use disorder are similar for both pregnant and non-pregnant women. However, opioid use disorder carries obstetrical risks for pregnant women. The Pregnant Women Webinar will provide an overview of the recommendations and in-depth information on treating pregnant women from ASAM's National Practice Guideline.
This webinar is primarily intended for clinicians involved in evaluating patients and providing authorization for pharmacological treatments at any level.
At the conclusion of the webinar, participants should be able to:
- Recognize epidemiology of opioid use disorder and the treatment gap among patients misusing opioids and heroin.
- Summarize the guideline's treatment recommendations for special populations and discuss how they should be used in practice.
- Identify the fundamental components of an OUD patient assessment and diagnosis for special populations with opioid use disorders.
- Discuss the unique needs and treatment recommendations for pregnant women.
The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
ASAM designates this live activity for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Addiction Medicine (ABAM) MOC:
This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of .75 AMA PRA Category 1 Credits™.
|Adam J. Gordon, MD, MPH, FACP, FASAM, CMRO, Chair, Reviewer||None|
Catherine Friedman, MD, Vice Chair, Reviewer
|Noel Ilogu, MD, MRCP||None|
|Herbert L. Malinoff, MD, FACP, FASAM||None|
|Edwin A. Salsitz, MD, FASAM, Reviewer||None|
|John C. Tanner, DO, FASAM, CCFC, MRO||
Reckitt-Benckiser: Honorarium, Speaker
Orexo: Honorarium, Speaker
BDSI: Honorarium, Speaker & Consultant
|Adam J. Gordon, MD, MPH, FACP, FASAM, CMRO||None|
|Margaret A. E. Jarvis, MD, FASAM||
Geisinger Health System: Salary, Medical Director
US Preventive Health: Dividend, Stockholder
Hoffspiegel and Associates: Fees, Expert Witness
Up-to-Date: Royalties, Author
|Robert J. Roose, MD, MPH||Health New England, Inc.: Honorarium, Behavioral Health Advisory Committee, Associate Medical Director|
|Marc Fishman, MD, DFASAM||
Maryland Treatment Centers: Employment, Ownership Interest includes stock, stock options, patent or other intellectual property
US World Meds: Consultant/Advisory Board, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received
|Aaron D. Fox, MD, MS||None|
|Brian Hurley, MD, MBA, DFASAM||None|
|Yngvild Olsen, MD, MPH, FASAM||None|
|Tricia Wright, MD, MS, FACOG, FASAM||None|
MD, MS, FACOG, FASAM
Tricia Wright, MD MS is an assistant professor of Obstetrics, Gynecology and Women's Health at the University of Hawaii John A. Burns School of Medicine and founder, former medical director, and now Women's Health Liaison of the PATH Clinic, an outreach clinic of Waikiki Health Center, which provides prenatal, postpartum and family planning to women with a history of substance use disorders. She is board certified in both Ob/Gyn and Addiction Medicine and a Fellow of the American College of Obstetrics and Gynecology. She has been waivered to provide buprenorphine since 2009, and has treated both pregnant and non-pregnant women. She won funding approval in 2006 from the Hawaii legislature to start a perinatal clinic for women with substance use, the first in the state. The Path Clinic opened in 2007, and has seen over 400 pregnant women since that time. She completed her Masters Degree in Clinical Research from the University of Hawaii in 2009, her thesis paper studying the disparities of smoking and drug use rates during pregnancy of Native Hawaiian women. Her research interests include substance use disorders among pregnant women, including barriers to family planning, screening, brief intervention and referral to treatment (SBIRT), best practices for treatment, and the effects of methamphetamine, marijuana and tobacco on the placenta.